Back to search

National and Kapodistrian University of Athens

Προοπτική μελέτη υπερηχογραφικών δεικτών συστολικής και διαστολικής λειτουργίας της αριστερής κοιλίας σε ογκολογικούς ασθενείς οι οποίοι λαμβάνουν συστηματική χορήγηση bevacizumab

Abstract

dc:description

Abstract Background: Bevacizumab, is an anti-angiogenic agent recently used widely in the treatment of cancer. Limited data support an increase of the thrombotic events in patients receiving bevacizumab. Objectives: The aim of the present study was to evaluate the incidence of cardiovascular events in patients treated with bevacizumab, and to identify prognostic clinical, electrocardiographic, and echocardiographic factors of the effect of bevacizumab on cardiovascular system.Methods: One hundred and forty seven patients were prospectively included in the study. The patients were divided into two groups. Group 1 received conventional chemotherapeutic scheme with bevacizumab and group 2 similar chemotherapeutic schemes without bevacizumab. All patients were prospectively followed up at 6 and 18 months. Results: Seventy six patients (65.21±10.49 years) were treated with bevacizumab and 71 patients (65.11±11.3 years) without bevacizumab. Cardiovascular events were higher in the bevacizumab group compared to the controls (7/76 [9.21%] versus 1/71 [1.40%], p=0.03). From the echocardiographic indexes evaluating the myocardial systolic function, the Sa was lower both at 6 and 18 months (10.93±4.64 versus 9.90±3.59 cm/s, p<0.001 and 10.93±4.64 vs 9.03±9.56 cm/s, p=0.003). Regarding the diastolic function, E/E΄ ratio increased both at 6 months and at 18 months (5.83±2.53 vs 7.86±3.45, p<0.001 and 5.83±2.53 vs 7.84±3.45, p= 0.004). Multivariate analysis identified left bundle branch block (LBBB), and bevacizumab as independent predictors of cardiovascular events. (p<0.001 HR: 56.72, for LBBB and p=0.03, HR: 13.18, for bevacizumab)Conclusion: Bevacizumab is associated with increased incidence of cardiovascular events and has impact in systolic and diastolic function of left ventricle. LBBB is an independent risk factor for future cardiovascular events.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kapelakis, Ioannis
  • Καπελάκης, Ιωάννης

Subjects

dc:subject × 8

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/40761

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kapelakis, Ioannis; Καπελάκης, Ιωάννης. Προοπτική μελέτη υπερηχογραφικών δεικτών συστολικής και διαστολικής λειτουργίας της αριστερής κοιλίας σε ογκολογικούς ασθενείς οι οποίοι λαμβάνουν συστηματική χορήγηση bevacizumab. National and Kapodistrian University of Athens, 2017. http://hdl.handle.net/10442/hedi/40761